skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: THRM can you take a look at this penny stock .... it reads like a real potential success story ....
Read Answer Asked by Bob on December 15, 2020
Q: Could I have your thoughts on BioHaven. It has a new drug for acute treatment of migraine headaches and seems to be very effective. Their stock has progressed since the drug was first put on the market earlier this year. How do they look financially? I believe they have an interest in another company Kleo Pharmaceuticals. I believe The Bill & Melinda Gates Foundation has also given Kleo a substantial grant.
Thanks John
Read Answer Asked by John on December 15, 2020
Q: Hi Peter, I'm just wondering about any new views since the 3rd of Sept comment. Would this also be a good play on the vaccine investments for 2021. Each person needs 2 doses - that's a lot of syringes and needles! Would Becton benefit or is there too many competition suppliers out there (market share?) and/or doesn't make too much towards its total annual profits? Thanks.
Read Answer Asked by Michael on December 15, 2020
Q: Hi - huge pop on the IPO for AbCellera. Sounds promising, what would your take be on investing in it now? Better to wait for some of the enthusiasm to die down? Looks like it has a strong US following.
Read Answer Asked by Jason on December 14, 2020
Q: What portion of FHI distribution is return of capital? What would be your order of choice among LIFE; FHI; and HHL ?
Read Answer Asked by Terry on December 14, 2020
Q: Can you comment on any recent insider buying or selling for GUD. E.g. has the CEO bought any large chunks? I am curious if there has been some insider purchasing/selling either before or after the shelf filing. If there has been buying, what do you think are the odds that there might be an acquisition in the works. I bought GUD at $5 and am trying to decide whether to hold, sell, or top up. Because everything else in my portfolio has done so well this year (all fantastic 5i suggestions), GUD has decreased to 1.3% of total holdings.
Read Answer Asked by Justin on December 14, 2020
Q: Hi guys. Would you be able to tell me your ratings on these medical stocks for growth and risk please. It would be a 3 year time frame minimum. Thks again for the great job you do.
Read Answer Asked by wilson on December 14, 2020
Q: Hello 5i
Could I have your opinion in PNSL please?
Also who would their competitors be?
Thank you
Dave
Read Answer Asked by Dave on December 11, 2020
Q: I HAVE HELD THESE STOCKS FOR ALMOST YEAR AND A HALF, HOPING THE STOCKS WILL MOVE UP AS THE VACCINES BECOME AVAILABLE. I FIND THAT NONE OF THESE STOCKS HAVE MOVED UP EXCEPT VEEV, AND THAT TOO MARGINALLY. SHOULD I KEEP THESE STOCKS OR SELL THEM AND USE THE MONEY FOR OTHER PROMISING TECH STOCKS. THANKS
Read Answer Asked by Vinod on December 10, 2020
Q: I have a DOY balanced portfolio (Alpha-Balanced for guidance) , with less than 10 year timeframe.
I’m underweight communication services, and energy. Not a fan at this stage of oil or precious metals. Overweight in industrials and technology.
My concern is with my overweight in technology. Reading a number of opinion articles that refer to the tech boom as another dot.com. The reply often is oh but this is different.
Here’s my two cents worth especially related to tech stocks I own. First of all investors/traders seem to be jumping in and out of technology based on the latest COVID-19 / vaccine news.
Re KXS; will still be in demand long after Covid-19. LSPD; somewhat sensitive to Covid-19 but have done a good job diversifying and adapting restaurant services etc. Will do well in recovery.
Maybe more acquisitions.
SHOP; like Amazon will carry on even though the valuation is high. Younger generation will still shop on line.
Now comes the tricky part. WELL and VEEV. I don’t quite have a handle on. Not sure if the demand for their service will still be there post COVID-19.
Your comments and/or thought would be greatly appreciated. I have a feeling that many of your clients would be interested in what you have to say.
I’m an experienced investor but don’t have access to the kinds of info I once did. I depend a great deal on your unbiased expert opinion.
Merry Christmas

Roy
Read Answer Asked by Roy on December 10, 2020
Q: Atara Biotherapeutics (NASDAQ:ATRA) has announced presentation of preclinical data of ATA3219 at American Society of Hematology.
Their allogeneic CAR T-cell therapy targeting CD19, Bayer has also just entered into an exclusive worldwide license agreement, for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors with Atara.
What is your opinion on this company and it's medium and long term investment potential.
Read Answer Asked by Rajesh on December 10, 2020
Q: Good morning, I have a watch-list of vaccines, but it seemed like such a gamble in the past months, I didn't invest in any. Now that some are successful, I would like to have a position in at least one company. I've named a few above, but there are more. With the goal of growth in the next 1-2 years, which one or two "vaccine" stocks would you choose, and what percentage of the portfolio would you suggest as investment size. Thank-you.
Read Answer Asked by Kim on December 09, 2020